CD274 and adenocarcinoma: In a study conducted by Jovanovic et al. [23], 47% of EGFRmut adenocarcinoma patients had high sPD-L1, i.e., all patients who were PD-L1-positive (these patients had advanced disease), 43% of patients with EGFRwt NSCLC, 64% of patients with squamous cell carcinoma, and 31% of patients with SCLC.